Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers

NCT02964182 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2025-12-09

Study results available
· View outcomes & findings →

Summary

This trial studies what would happen if the nicotine levels in cigarettes are greatly reduced, but electronic cigarettes containing different amount of nicotine are available. Different levels of nicotine may effect certain behaviors, including withdrawal symptoms, nicotine cravings, and mood and may lead to changes in smoking behavior in current daily and intermittent smokers..

Conditions

  • Cigarette Smoking-Related Carcinoma
  • Tobacco-Related Carcinoma

Interventions

DRUG

Cigarette

Smoke usual brand of cigarettes

DRUG

Nicotine Replacement

Received NRT (Electronic Cigarette - ECIG-Hi)

DRUG

Nicotine Replacement

Received NRT (Electronic Cigarette - ECIG-Hi)

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Survey Administration

Ancillary studies

DRUG

Very Low Nicotine Content Cigarette

Smoke very low nicotine content cigarette

DEVICE

ECIG-Hi

Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.

DEVICE

ECIG-Lo

Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH
  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Paul Cinciripini · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-26
Primary Completion
2025-03-04
Completion
2025-03-04
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02964182 on ClinicalTrials.gov